Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis

Proteomics - Clinical Applications

Volumn 2, Issue 3, 2008, Pages 372-386

  Kumari, Shraddha ^a   Kumar, Awanish ^a   Samant, Mukesh ^a   Sundar, Shyam ^b   Singh, Neeloo ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Diagnostics; Drug resistance; Drug targets; Vaccine; Visceral Leishmaniasis

Indexed keywords

AMPHOTERICIN B; ANTIMONY DERIVATIVE; METHOTREXATE; MILTEFOSINE; PARASITE ANTIGEN; PENTAMIDINE;

DRUG TARGETING; GENE EXPRESSION REGULATION; GENE MAPPING; HOST PARASITE INTERACTION; HUMAN; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARASITE SERODIAGNOSIS; PARASITE SURVIVAL; PARASITE VIRULENCE; PARASITOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS;

LEISHMANIA DONOVANI; LEISHMANIA DONOVANI CHAGASI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR;

EID: 41149091679     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780017     Document Type: Review

References (104)

1. Pearson, R. D., Souza, A. Q., Jeronimo, S. M. B., Principles and Practice of Infectious Diseases. Churchill Livingstone, Philadelphia 2000, pp. 2831-2844.
2. Pearson, R. D., Lareau, S. M., Jeronimo, S. M., Leishmaniasis at the end of the millennium. Curr. Infect. Dis. Rep. 1999, 1, 448-452.
3. Davidson, R. N., Visceral leishmaniasis in clinical practice. J. Infect. 1999, 39, 112-116.
4. Gradoni, L., Epizootiology of canine leishmaniasis in southern Europe: An update. Proc. Int. Canine Leishmaniasis Forum. Wiesbaden, Germany 1999, pp. 32-39.
5. Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser. 1990, 793, 1-158.
6. Croft, S. L., Seifert, K., Yardley, V., Current scenario of drug development far leishmaniasis. Indian J. Med. Res. 2006, 123, 399-410. 7 Sundar, S., Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001, 6, 849-854.
7. Handman, E., Leishmaniasis: Current status of vaccine development. Clin. Microbiol. Rev. 2001, 14, 229-243.
8. Hunter, T. C., Andon, N. L., Koller, A., Yates, J. R., Haynes, P. A., The functional proteomics toolbox: Methods and applications. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 782, 165-181.
9. Cash, P., Proteomics of bacterial pathogens. Adv. Biochem. Eng. Biotechnol. 2003, 83, 93-115.
10. Cohen, A. M., Rumpel, K., Coombs, G. H., Wastling, J. M., Characterisation of global protein expression by two-dimensional electrophoresis and mass spectrometry: Proteomics of Toxoplasma gondii. Int. J. Parasitol. 2002, 32, 39-51.
11. Barrett, J., Jefferies, J. R., Brophy, P. M., Parasite proteomics. Parasitol. Today 2000, 16, 400-403.
12. Paba, J., Santana, J. M., Teixeira, A. R., Fontes, W. et al., Proteomic analysis of the human pathogen Trypanosoma cruzi. Proteomics 2004, 4, 1052-1059.
13. El Fakhry, Y., Ouellette, M., Papadopoulou, B., A proteomic approach to identify developmentally regulated proteins in Leishmania infantum. Proteomics 2002, 2, 1007-1017.
14. Bente, M., Harder, S., Wiesgigl, M., Heukeshoven, J. et al., Developmentally induced changes of the proteome in the protozoan parasite Leishmania donovani. Proteomics 2003, 3, 1811-1829.
15. Grandi, G., Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol. 2001, 19, 181-188.
16. Marshall, T., Williams, K. M., Proteomics and its impact upon biomedical science. Br. J. Biomed. Sci. 2002, 59, 47-64.
17. Geibler, S., Sokolowska-Köhler, W., Bollmann, R., Jungblut, P. R., Presber, W., Toxoplasma gondii infection: Analysis of serological response by 2-DE immunoblotting. FEMS Immunol. Med. Microbiol. 1999, 25, 299-311.
18. Dlugonska, H., Dytnerska, K., Reichmann, G., Stachelhaus, S., Fischer, H. G., Towards the Toxoplasma gondii proteome: Position of 13 parasite excretory antigens on a standardized map of two-dimensionally separated tachyzoite proteins. Parasitol. Res. 2001, 87, 634-637.
19. Kirinoki, M., Yokoi, H., Kawai, S., Chigusa, Y., Matsuda, H., Detection of a Schistosoma japonicum specific circulating antigen by two-dimensional gel electrophoresis. Parasitol. Int. 1998, 47, 21-27.
20. Kasuga-Aoki, H., Tsuji, N., Suzuki, K., Isobe, T., Yoshihara, S., Identification of surface proteins and antigens from larval stages of Ascaris suum by two-dimensional electrophoresis. Parasitology 2000, 121, 671-677.
21. Heckeroth, A. R., Tenter, A. M., Hemphill, A., Innes, E. A., Buxton, D., Evaluation of crossreactivity between tachyzoites of Neospora caninum and Toxoplasma gondii by two-dimensional gel electrophoresis. Int. J. Parasitol. 2000, 30, 913-919.
22. Lee, E. G., Kim, J. H., Shin, Y. S., Shin, G. W. et al., Establishment of a two-dimensional electrophoresis map for Neospora caninum tachyzoites by proteomics. Proteomics 2003, 3, 2339-2350.
23. Fernandez-Arenas, E., Molero, G., Nombela, C., Diez-Orejas, R., Gil, C., Low virulent strains of Candida albicans: Unravelling the antigens for a future vaccine. Proteomics 2004, 4, 3007-3020.
24. Sudhir, S., Shalini, A., Kosalai, K., Namane, A. et al., Proteome analysis of the plasma membrane of Mycobacterium tuberculosis. Comp. Funct. Genomics 2002, 3, 470-483.
25. Sinha, S., Kosalai, K., Arora, S., Namane, A. et al., Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology 2005, 151, 2411-2419.
26. Thiel, M., Bruchhaus, I., Comparative proteome analysis of Leishmania donovani at different stages of transformation from promastigotes to amastigotes. Med. Microbiol. Immunol. 2001, 190, 33-36.
27. Nugent, P. G., Karsani, S. A., Wait, R., Tempero, J., Smith, D. F., Proteomic analysis of Leishmania mexicana differentiation. Mol. Biochem. Parasitol. 2004, 136, 51-62.
28. Araujo-Soares, R. M., Souza dos Santos, A. L., Ronaldo, M. C., Leishmania (Leishmania) amazonensis: Differential expression of proteinases and cell-surface polypeptides in avirulent and virulent promastigotes. Exp. Parasitol. 2003, 104, 104-112.
29. Drummelsmith, J., Brochu, V., Girard, I., Messier, N., Ouellette, M., Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteomics 2003, 2, 146-155.
30. Ouellette, M., Drummelsmith, J., Papadopoulou, B., Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist. Updat. 2004, 7, 257-266.
31. Gradoni, L., An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 2001, 100, 87-103.
32. Arora, S. K., Pal, N. S., Mujtaba, S., Leishmania donovani: Identification of novel vaccine candidates using human reactive sera and cell lines. Exp. Parasitol. 2005, 109, 163-170.
33. Lemesre, J. L., Holzmuller, P., Cavaleyra, M., Goncalves, R. B. et al., Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23, 2825-2840.
34. Molano, I., Alonso, M. G., Miron, C., Redondo, E. et al., A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 2003, 92, 1-13.
35. Passos, S., Carvalho, L. P., Orge, G., Jeronimo, S. M. et al., Recombinant leishmania antigens for serodiagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 2005, 12, 1164-1167.
36. Murray, H. W., Berman, J. D., Davies, C. R., Saravia, N. G., Advances in leishmaniasis. Lancet 2005, 366, 1561-1577.
37. Santarem, N., Tomas, A., Ouaissi, A., Tavares. J. et al., Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunol. Lett. 2005, 101, 18-23.
38. Kamoun-Essghaier, S., Guizani, I., Strub, J. M., Van Dorsselaer, A. et al., Proteomic approach for characterization of immunodominant membrane-associated 30- to 36-kiloDalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from Mediterranean visceral leishmaniasis patients. Clin. Diagn. Lab. Immunol. 2005, 12, 310-320.
39. Acestor, N., Masina, S., Walker, J., Saravia, N. G. et al., Establishing two-dimensional gels for the analysis of Leishmania proteomes. Proteomics 2002, 2, 877-879.
40. McNicoll, F., Drummelsmith, J., Muller, M., Madore, E. et al., A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics 2006, 6, 3567-3581.
41. Foucher, A. L., Papadopoulou, B., Ouellette, M., Pre-fractionation by digitonin extraction increases representation of the cytosolic and intracellular proteome of Leishmania infantum. J. Proteome. Res. 2006, 5, 1741-1750.
42. Schulz, I., Permeabilizing cells: Some methods and applications for the study of intracellular processes. Methods Enzymol. 1990, 192, 280-300.
43. Bijleveld, C., Geelen, M. J., Measurement of acetyl-CoA carboxylase activity in isolated hepatocytes. Biochim. Biophys. Acta. 1987, 918, 274-283.
44. Brobey, R. K., Soong, L., Establishing a liquid-phase IEF in combination with 2-DE for the analysis of Leishmania proteins. Proteomics 2007, 7, 116-120.
45. Graves, P. R., Haystead, T. A., Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 2002, 66, 39-63.
46. Lasonder, E., Ishihama, Y., Andersen, J. S., Vermunt, A. M., Pain, A., Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 2002, 419, 537-542.
47. McCormack, A. L., Schieltz, D. M., Goode, B., Yang, S., Barnes, G., Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal. Chem. 1997, 69, 767-776.
48. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
49. Leifso, K., Cohen-Freue, G., Dogra, N., Murray, A., McMaster, W. R., Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: The Leishmania genome is constitutively expressed. Mol. Biochem. Parasitol. 2007, 152, 35-46.
50. Soong, L., Chang, C. H., Sun, J., Langley, B. J., Jr. et al., Role of CD4+ Tcells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 1997, 158, 5374-5383.
51. Ji, J., Sun, J., Soong, L., Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect. Immun. 2003, 71, 4278-4288.
52. Ji, J., Masterson, J., Sun, J., Soong, L., CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J. Immunol. 2005, 174, 7147-7153.
53. Cordwell, S. J., Nouwens, A. S., Walsh, B. J., Comparative proteomics of bacterial pathogens. Proteomics 2001, 1, 461-472.
54. Brobey, R. K., Mei, F. C., Cheng, X., Soong, L., Comparative two-dimensional gel electrophoresis maps for promastigotes of Leishmania amazonensis and Leishmania major. Braz. J. Infect. Dis. 2006, 10, 1-6.
55. Cuervo, P., de Jesus, J. B., Junqueira, M., Mendonca-Lima, L. et al., Proteome analysis of Leishmania (Viannia) braziliensis by two-dimensional gel electrophoresis and mass spectrometry. Mol. Biochem. Parasitol. 2007, 154, 6-21.
56. Gongora, R., Acestor, N., Quadroni, M., Fasel, N. et al., Mapping the proteome of Leishmania Viannia parasites using two-dimensional polyacrylamide gel electrophoresis and associated technologies. Biomedica 2003, 23, 163-160.
57. Walker, J., Vasquez, J. J., Gomez, M. A., Drummelsmith, J. et al., Identification of developmentally-regulated proteins in Leishmania panamensis by proteome profiling of promastigotes and axenic amastigotes. Mol. Biochem. Parasitol. 2006, 147, 64-73.
58. Croan, D. G., Morrison, D. A., Ellis, J. T., Evolution of the genus Leishmania revealed by comparison of DNA and RNA polymerase gene sequences. Mol. Biochem. Parasitol. 1997, 89, 149-159.
59. Noyes, H. A., Camps, A. P., Chance, M. L., Leishmania herreri (Kinetoplastida; Trypanosomatidae) is more closely related to Endotrypanum (Kinetoplastida; Trypanosomatidae) than to Leishmania. Mol. Biochem. Parasitol. 1996, 80, 119-123.
60. Glaser, T. A., Moody, S. F., Handman, E., Bacic, A., Spithill, T. W., An antigenically distinct lipophosphoglycan on amastigates of Leishmania major. Mol. Biochem. Parasitol. 1991, 45, 337-344.
61. MacFarlane, J., Blaxter, M. L., Bishop, R. P., Miles, M. A., Kelly, J. M., Identification and characterisation of a Leishmania danovani antigen belonging to the 70 kDa heat-shock protein family. Eur. J. Biochem. 1990, 190, 377-384.
62. Turco, S. J., Sacks, D. L., Expression of a stage-specific lipophosphoglycan in Leishmania major amastigotes. Mol. Biochem. Parasitol. 1991, 45, 91-99.
63. Goyard, S., Segawa, H., Gordon, J., Showalter, M. et al., An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol. Biochem. Parasitol. 2003, 130, 31-42.
64. Zilberstein, D., Shapira, M., The role of pH and temperature in the development of Leishmania parasites. Annu. Rev. Microbiol. 1994, 48, 449-470.
65. Kumar, A., Katiyar, S. B., Gupta, S., Chauhan, P. M., Syntheses of new substituted triazino tetrahydroisoquinolines and beta-carbolines as novel antileishmanial agents. Eur. J. Med. Chem. 2006, 41, 106-113.
66. Garg, R., Gupta, S. K., Tripathi, P., Hajela, K. et al., Leishmania donovani. Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 2006, 24, 2900-2909.
67. Gupta, S. K., Sisodia, B. S., Sinha, S., Hajela, K. et al., Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 2007, 7, 816-823.
68. Ribeiro, J. M., Vector salivation and parasite transmission. Mem. Inst. Oswaldo Cruz 1987, 82, 1-3.
69. Lerner, E. A., Ribeiro, J. M., Nelson, R. J., Lerner, M. R., Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. J. Biol. Chem. 1991, 266, 11234-11236. 71 Charlab, R., Valenzuela, J. G., Rowton, E. D., Ribeiro, J. M., Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomyia longipalpis. Proc. Natl. Acad. Sci. USA 1999, 96, 5155-15160.
70. Gillespie, R. D., Mbow, M. L., Titus, R. G., The immunomodulatory factors of blood-feeding arthropod saliva. Parasite. Immunol. 2000, 22, 319-331.
71. Valenzuela, J. G., Garfield, M., Rowton, E. D., Pham, V. M., Identification of the most abundant secreted proteins from the salivary glands of the sand fly Lutzomyia longipalpis, vector of Leishmania chagasi. J. Exp. Biol. 2004, 207, 3717-3729.
72. Dea-Ayuela, M. A., Rama-Iniguez, S., Bolas-Fernandez, F., Proteomic analysis of antigens from Leishmania infantum promastigotes. Proteomics 2006, 6, 4187-4194.
73. Forgber, M., Basu, R., Roychoudhury, K., Theinert, S. et al., Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS ONE 2006, 1, e40.
74. Agranoff, D., Fernandez-Reyes, D., Papadopoulos, M., Identification of diagnostic markers for tuberculosis by serum proteomic fingerprinting. Lancet Infect. Dis. 2006, 140, 69342-69352.
75. Issaq, H. J., Veenstra, T. D., Conrads, T. P., Felschow, D., The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem. Biophys. Res. Comm. 2002, 292, 587-592.
76. Adam, B. L., Qu, Y., Davis, J. W., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostatic hyperplasia and healthy men. Cancer Res. 2002, 62, 3609-3614.
77. Petri coin, E. F., Ardekani, A. M., Hitt, B. A., Use of proteomic patterns in serum to identify ovarian cancer. Lancet Infect. Dis. 2002, 359, 572-577. 80 Papadopoulos, M. C., Abel, P. M., Agranoff, D., A novel and accurate diagnostic test for human African trypanosomiasis. Lancet Infect. Dis. 2004, 363, 1358-1363.
78. Hettick, J. M., Kashon, M. L., Simpson, J. P., Siegel, P. D., Mazurek, G. H., Proteomic profiling of intact Mycobacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 2004, 76, 5769-5776.
79. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J., Mondal, M., Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophorosis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
80. Rafati, S., Hassani, N., Taslimi, Y., Movassagh, H. et al., Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin. Vaccine Immunol. 2006, 13, 1104-1110.
81. Guerin, P. J., Olliaro, P., Sundar, S., Boelaert, M. et al., Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2002, 2, 494-501.
82. Croft, S. L., Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health 2001, 6, 899-905.
83. Rojas, R., Valderrama, L., Valderrama, M., Varona, M. X. et al., Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 2006, 193, 1375-1383.
84. Hadighi, R., Mohebali, M., Boucher, P., Hajjaran, H. et al., Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006, 3, e162.
85. Lira, R., Sundar, S., Makharia, A., Kenney, R. et al., Evidence that the high incidence of treatment failures in Indian kalaazar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 1999, 180, 564-567.
86. McAtee, C. P., Hoffman, P. S., Berg, D. E., Identification of differentially regulated proteins in metronidozole resistant Helicobacter pylori by proteome techniques. Proteomics 2001, 1, 516-521. 2 90 Soualhine, H., Brochu, V., Menard, F., Papadopoulou, B., Weiss, K., A proteomic analysis of penicillin resistance in Streptococcus pneumoniae reveals a novel role for PstS, a subunit of the phosphate ABC transporter. Mol. Microbiol. 2005, 58, 1430-1440.
87. Hooshdaran, M. Z., Barker, K. S., Hilliard, G. M., Kusch, H., Morschhauser, J., Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 2004, 48, 2733-2735.
88. Foucher, A. L., McIntosh, A., Douce, G., Wastling, J., Tait, A., A proteomic analysis of arsenical drug resistance in Trypanosoma brucei. Proteomics 2006, 6, 2726-2732.
89. Ouellette, M., Legare, D., Haimeur, A., Grondin, K. et al., ABC transporters in Leishmania and their role in drug resistance. Drug. Resist. Updat. 1998, 1, 43-48.
90. Ouellette, M., Drummelsmith, J., El-Fadili, A., Kundig, C. et al., Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. Int. J. Parasitol. 2002, 32, 385-398.
91. Croft, A. M., Lestringant, G. G., Baker, B. C., Cutaneous leishmaniasis following military deployment to Iraq. Med. Trop. (Mars) 2006, 66, 185-188.
92. Faraut-Gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B. et al., In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 1997, 41, 827-830.
93. Singh, N., Singh, R. T., Sundar, S., Novel mechanism of drug resistance in kala azar field isolates. J. Infect. Dis. 2003, 188, 600-607.
94. Decuypere, S., Vandesompele, J., Yardley, V., De Donckeri, S. et al., Differential polyadenylation of ribosomal RNA during post-transcriptional processing in Leishmania. Parasitology 2005, 131, 321-329.
95. Vergnes, B., Gourbal, B., Girard, I., Sundar, S. et al., A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol. Cell. Proteomics 2007, 6, 88-101.
96. Decuypere, S., Rijal, S., Yardley, V., De Doncker, S. et al., Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob. Agents Chemother. 2005, 49, 4616-4621.
97. Kothari, H., Kumar, P., Singh, N., Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate. Protein Expr. Purif. 2006, 45, 15-21.
98. Singh, N., Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J. Med. Res. 2006, 123, 411-422.
99. Dube, A., Singh, N., Sundar, S., Singh, N., Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in In vitro and in vivo experimental models. Parasitol. Res. 2005, 96, 216-223.
100. Zhang, C. G., Chromy, B. A., McCutchen-Maloney, S. L., Host-pathogen interactions: A proteomic view. Expert. Rev. Proteomics 2005, 2, 187-202.
101. Phillips, C. I., Bogyo, M., Proteomics meets microbiology: Technical advances in the global mapping of protein expression and function. Cell. Microbiol. 2005, 7, 1061-1076.
102. Nirmalan, N., Sims, P. F., Hyde, J. E., Quantitative proteomics of the human malaria parasite Plasmodium falciparum and its application to studies of development and inhibition. Mol. Microbiol. 2004, 52, 1187-1199.
103. Greenbaum, D. C., Baruch, A., Grainger, M., Bozdech, Z. et al., A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 2002, 298, 2002-2006.
104. Walker, J., Acestor, N., Gongora, R., Quadroni, M. et al., Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Mol. Biochem. Parasitol. 2006, 145, 254-264.